CN1418095A - 眼生长和烟碱拮抗剂 - Google Patents

眼生长和烟碱拮抗剂 Download PDF

Info

Publication number
CN1418095A
CN1418095A CN01806785A CN01806785A CN1418095A CN 1418095 A CN1418095 A CN 1418095A CN 01806785 A CN01806785 A CN 01806785A CN 01806785 A CN01806785 A CN 01806785A CN 1418095 A CN1418095 A CN 1418095A
Authority
CN
China
Prior art keywords
eye
nicotinic
nicotinic antagonists
antagonists
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01806785A
Other languages
English (en)
Chinese (zh)
Inventor
理查德·A·斯通
乔恩·M·林德斯特伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
VALLEY FORGE PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VALLEY FORGE PHARMACEUTICALS Inc filed Critical VALLEY FORGE PHARMACEUTICALS Inc
Publication of CN1418095A publication Critical patent/CN1418095A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN01806785A 2000-01-18 2001-01-18 眼生长和烟碱拮抗剂 Pending CN1418095A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17687500P 2000-01-18 2000-01-18
US60/176,875 2000-01-18

Publications (1)

Publication Number Publication Date
CN1418095A true CN1418095A (zh) 2003-05-14

Family

ID=22646232

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01806785A Pending CN1418095A (zh) 2000-01-18 2001-01-18 眼生长和烟碱拮抗剂

Country Status (10)

Country Link
EP (1) EP1272170A1 (ja)
JP (1) JP2003520228A (ja)
KR (1) KR20020081260A (ja)
CN (1) CN1418095A (ja)
AU (1) AU775516B2 (ja)
CA (1) CA2400803A1 (ja)
HK (1) HK1052464A1 (ja)
MX (1) MXPA02007039A (ja)
RU (1) RU2002120485A (ja)
WO (1) WO2001052832A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2633655A1 (en) * 2005-12-19 2007-07-05 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses therof
FI20075498A (fi) 2007-06-29 2008-12-30 Eero Castren Menetelmä amblyopian hoitamiseksi masennuslääkkeillä
EP3593817A4 (en) * 2017-03-06 2021-04-07 Tsubota Laboratory, Inc. MODEL FOR THE INDUCTION OF MURINE MYOPIA AND ENDOPLASMATIC RETICULUM STRESS INHIBITOR FOR THE PREVENTION OR SUPPRESSION OF MYOPIA
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69029734T2 (de) * 1989-06-21 1997-05-28 Univ Pennsylvania Verwendung von Pirenzepine, Telenzepine oder O-Methoxy -sila-hexocyclium zur Herstellung eines Medikaments zur BEHANDLUNG UND REGULIERUNG DER AUGENENTWICKLUNG
WO1998030900A2 (en) * 1997-01-06 1998-07-16 Klaus Trier Aps Screening method for compounds active in treating myopia and hypermetropia

Also Published As

Publication number Publication date
MXPA02007039A (es) 2003-09-25
JP2003520228A (ja) 2003-07-02
RU2002120485A (ru) 2004-04-10
CA2400803A1 (en) 2001-07-26
KR20020081260A (ko) 2002-10-26
AU775516B2 (en) 2004-08-05
HK1052464A1 (zh) 2003-09-19
AU3096901A (en) 2001-07-31
WO2001052832A1 (en) 2001-07-26
EP1272170A1 (en) 2003-01-08

Similar Documents

Publication Publication Date Title
Stone et al. Effects of nicotinic antagonists on ocular growth and experimental myopia
CN102006887B (zh) 初原纤维形式β-淀粉样蛋白的特异性抗体
De la Herrán-Arita et al. Current and emerging options for the drug treatment of narcolepsy
CN101415435A (zh) 用于治疗精神疾病和病症的支链淀粉和支链淀粉激动剂
EA010159B1 (ru) Способы лечения боли введением антагониста фактора роста нервов и нестероидного противовоспалительного средства и содержащие их композиции
CN107206009A (zh) 用于治疗视觉障碍的组合物和方法
WO2006039327A2 (en) Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve
US10945980B2 (en) Treatment for myopia
US20210330646A1 (en) Fascin binding compounds for spinogenesis
US20050054734A1 (en) Therapeutic treatment for the metabolic syndrome, type2 diabetes, obesity, or prediabetes
CN1418095A (zh) 眼生长和烟碱拮抗剂
US20050054652A1 (en) Methods of treating metabolic syndrome using dopamine receptor agonists
US20030096831A1 (en) Ocular growth and nicotinic antagonists
JPH078805B2 (ja) 眼の発育の神経ペプチド制御
CN114929742A (zh) 用三叶因子家族成员2调节剂治疗衰老相关损伤的方法和组合物
JP2009526833A (ja) 代替療法を最適化し、薬局方を全体的な嗜癖の治療に拡大適用するための新規な薬剤組成物
CN1074606A (zh) 在轴性近视的治疗中使用m1选择性抗毒蕈碱的吡啶苯并二氮酮的方法
JP2019069957A (ja) 抗（＋）メタンフェタミンモノクローナル抗体
US20180318379A1 (en) Inhibition of triggering receptor expressed on myeloid cells 1 (trem1) to treat central nervous system disorders
WO2007127151A2 (en) Non-human model of autoimmune disease
JP2023529374A (ja) レボカバスチン、選択的ヒスタミンｈ１受容体アンタゴニスト、及びその誘導体を用いて近視を予防及び治療するための方法及び組成物
Ishikawa et al. Effects of single and repeated administration of methamphetamine or morphine on neuroglycan C gene expression in the rat brain
TWI508976B (zh) 對β－類澱粉蛋白之基原纖維形式具專一性之抗體
US20040266677A1 (en) Method of diagnosing and treating lens illnesses using human HSF4 gene and coded product thereof
US20090048146A1 (en) Use of agents that upregulate crystallin expression in the retina and optic nerve head

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: UNIV PENNSYLVANIA

Free format text: FORMER OWNER: VALLEY FORGE PHARMACEUTICALS, INC.

Effective date: 20031201

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20031201

Address after: Philadelphia USA

Applicant after: The Trustees of The University of Pennsylvania

Address before: American California

Applicant before: Valley Forge Pharmaceuticals, Inc.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication